Synopsis
FDA granted accelerated approval for this indication in 2021. 6/11/2025 FDA approves darolutamide for metastatic castration-sensitive prostate cancer On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for metastatic castration-sensitive prostate cancer (mCSPC).
Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.
Read the full story at FDA: drugs ↗
